Liquid Biopsy, ctDNA Diagnosis through NGS
Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains information of genetic alterations. Compared to tissue...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/9/890 |
| _version_ | 1797518492501540864 |
|---|---|
| author | Chen Lin Xuzhu Liu Bingyi Zheng Rongqin Ke Chi-Meng Tzeng |
| author_facet | Chen Lin Xuzhu Liu Bingyi Zheng Rongqin Ke Chi-Meng Tzeng |
| author_sort | Chen Lin |
| collection | DOAJ |
| description | Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains information of genetic alterations. Compared to tissue biopsy, liquid biopsy possesses great advantages such as a less demanding procedure, minimal invasion, ease of frequent sampling, and less sampling bias. Next-generation sequencing (NGS) methods have come to a point that both the cost and performance are suitable for clinical diagnosis. Thus, profiling ctDNA by NGS technologies is becoming more and more popular since it can be applied in the whole process of cancer diagnosis and management. Further developments of liquid biopsy ctDNA testing will be beneficial for cancer patients, paving the way for precision medicine. In conclusion, profiling ctDNA with NGS for cancer diagnosis is both biologically sound and technically convenient. |
| first_indexed | 2024-03-10T07:30:44Z |
| format | Article |
| id | doaj.art-3b3795947d4b45219ef6c8691b79ada3 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T07:30:44Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-3b3795947d4b45219ef6c8691b79ada32023-11-22T13:55:26ZengMDPI AGLife2075-17292021-08-0111989010.3390/life11090890Liquid Biopsy, ctDNA Diagnosis through NGSChen Lin0Xuzhu Liu1Bingyi Zheng2Rongqin Ke3Chi-Meng Tzeng4School of Medicine, Huaqiao University, Quanzhou 362021, ChinaSchool of Medicine, Huaqiao University, Quanzhou 362021, ChinaTranslational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, ChinaSchool of Medicine, Huaqiao University, Quanzhou 362021, ChinaTranslational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, ChinaLiquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains information of genetic alterations. Compared to tissue biopsy, liquid biopsy possesses great advantages such as a less demanding procedure, minimal invasion, ease of frequent sampling, and less sampling bias. Next-generation sequencing (NGS) methods have come to a point that both the cost and performance are suitable for clinical diagnosis. Thus, profiling ctDNA by NGS technologies is becoming more and more popular since it can be applied in the whole process of cancer diagnosis and management. Further developments of liquid biopsy ctDNA testing will be beneficial for cancer patients, paving the way for precision medicine. In conclusion, profiling ctDNA with NGS for cancer diagnosis is both biologically sound and technically convenient.https://www.mdpi.com/2075-1729/11/9/890liquid biopsyctDNAnext-generation sequencingmutationbiomarkers |
| spellingShingle | Chen Lin Xuzhu Liu Bingyi Zheng Rongqin Ke Chi-Meng Tzeng Liquid Biopsy, ctDNA Diagnosis through NGS Life liquid biopsy ctDNA next-generation sequencing mutation biomarkers |
| title | Liquid Biopsy, ctDNA Diagnosis through NGS |
| title_full | Liquid Biopsy, ctDNA Diagnosis through NGS |
| title_fullStr | Liquid Biopsy, ctDNA Diagnosis through NGS |
| title_full_unstemmed | Liquid Biopsy, ctDNA Diagnosis through NGS |
| title_short | Liquid Biopsy, ctDNA Diagnosis through NGS |
| title_sort | liquid biopsy ctdna diagnosis through ngs |
| topic | liquid biopsy ctDNA next-generation sequencing mutation biomarkers |
| url | https://www.mdpi.com/2075-1729/11/9/890 |
| work_keys_str_mv | AT chenlin liquidbiopsyctdnadiagnosisthroughngs AT xuzhuliu liquidbiopsyctdnadiagnosisthroughngs AT bingyizheng liquidbiopsyctdnadiagnosisthroughngs AT rongqinke liquidbiopsyctdnadiagnosisthroughngs AT chimengtzeng liquidbiopsyctdnadiagnosisthroughngs |